Stent description and implantation Meo:DrugStar ST is a commercially available stainless steel, paclitaxel-coated stent produced in different sizes.Abstract The study was conducted to evaluate the clinical and angiographic results of the implantation of the paclitaxel-eluting stent Meo:DrugStar ST in patients with symptomatic coronary artery disease.
The Meo:DrugStar ST stent has a stainless steel stent platform with a homogenous non-biodegradable coating of paclitaxel mixed with a polyether-based biostable, monophase, and hemocompatible coating. Sixty patients with native coronary artery disease were included in the study. Immediate and long-term clinical and angiographic follow-up results were evaluated. There was a high proportion of patients with hypertension (55) according to JNC-VII. Mean stenosis ratio was 78 13, mean implanted stent diameter was 3.0 0.4 mm and mean length was 22 5 mm. Restenosis was detected in 4 (10) of those patients and 11 (27.5) of 40 patients had insignificant amount of restenosis. The results of this study indicate a potential benefit of the Meo:DrugStar ST stent for the prevention of stent thrombosis and restenosis in these relatively high-risk patients. Keywords: Meo:DrugStar ST stent, paclitaxel drug-eluting stent, coronary artery disease The development and widespread use of coronary stents has probably been the single most significant advance in the field of interventional cardiology over the last decade. The use of a stent at the time of coronary artery dilatation is now carried out in more than 70 of all intra-coronary angioplasty procedures and, in many ways, coronary angioplasty has become coronary stenting. Its exact role is still being debated and there is a proliferation of stent designs, stent technologies, and stent coatings which continue to challenge the interventional cardiologist to try and utilize them to their best ability. The increased cost of stenting represents financial challenges that have been taken up to a greater or lesser extent in different health-care systems and countries ( Serruys et al 1994 ). A breakthrough occurred in early 2000 with the development of stents that eluted pharmacology agents directly into the vessel wall by means of a controlled release from a durable polymer coating. Various drug-eluting stents (DES) were developed, each varying in delivery platform, polymer coating (or absence of coating), and drug selected for elution ( Pompa and Tulli 2006 ). The paclitaxel eluting stent (Meo:DrugStar ST, Germany) is a new DES. It has a stainless steel stent platform and a homogenous non-biodegradable coating of paclitaxel mixed with a polyether-based biostable, monophase, and hemocompatible coating. Paclitaxel release is completed within 28 days of implantation ( Figure 1 ). ![]() Open in a separate window Figure 1 The Meo:DrugStar ST stent. ![]() Using the commercially available, slow-release polymer formulation, 90 of the sirolimus contained on the stent is released within 30 days ( Moses et al 2003 ). The CYPHER stent was approved for clinical use in Europe in April 2002 and in the United States in May 2003. This stent is used in approximately 50 of DES procedures worldwide. Material and methods Patients Sixty patients were eligible for enrolment if there was symptomatic coronary artery disease or positive functional testing and angiographic evidence of single- or multi-vessel disease with a target lesion stenosis of 75 in a 2.5 mm vessel. Patients were excluded if there was left main disease (50), recent myocardial infarction (MI), (7 days), contraindications to anti-platelet therapy, or a need for 3 stents for 1 target site.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |